BMS.754807, an inhibitor targeting the insulin-like growth factor 1 receptor and insulin receptor family kinases, has been in phase I trials for the treatment of human cancers, including breast, lung, pancreatic, colon, and gastric tumor cell lines [59,60]. This evidence concerns the gene IGF1R and cancer.